Canada Royal Enoch Phytomedicine has achieved a significant milestone with its ginsenoside supplement Redsenol-1 Plus being included in the National Cancer Institute's (NCI) Drug Dictionary. This recognition represents the first such listing for a multi-component ginsenoside supplement and highlights the product's unique scientific profile.
The NCI Drug Dictionary entry defines Redsenol-1 Plus as an oral herbal supplement containing sixteen rare ginsenosides, distinguishing it from conventional ginseng extracts. Unlike typical supplements that contain approximately 4% total ginsenosides, Redsenol-1 Plus offers a 20% concentration of highly bioactive compounds.
The supplement's inclusion coincides with an ongoing clinical trial investigating its potential for mitigating cancer-related fatigue. The triple-blind, placebo-controlled study, conducted by KGK Science, Inc., could position Redsenol-1 Plus as an innovative solution for cancer patients experiencing treatment-related exhaustion.
Dr. Peihua Yu, founder and CEO of Canada Royal Enoch Phytomedicine, emphasized the significance of this standardized definition, noting the company's commitment to advancing scientific understanding of ginsenoside applications in cancer-related conditions.
The listing underscores the potential of specialized botanical supplements in oncology research and signals a growing recognition of alternative approaches to supportive cancer care. By providing a comprehensive profile of rare ginsenosides, Redsenol-1 Plus offers researchers and healthcare professionals a detailed reference point for further investigation.
